United Therapeutics : Treprostinil Data Presented at Annual Meeting of the American Thoracic Society

May 6, 2008 - United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. announced that data related to the four different routes of administration of the drug, treprostinil, for the treatment of pulmonary arterial hypertension will be presented at the annual meeting of the American Thoracic Society (ATS), to be held in Toronto, Ontario, beginning May 16th and ending May 21, 2008,
including the first public presentation of the full data set from the TRIUMPH-1 study of inhaled treprostinil... United Therapeutics Corporation's Press Release -

Aradigm : Trial of Lung Rx's Inhaled Treprostinil

April 8, 2008--Aradigm Corporation (OTCBB: ARDM) announced it initiated a bridging clinical trial of inhaled treprostinil utilizing its AERx Essence(R) pulmonary delivery system. The trial in healthy volunteers is being conducted in the United Kingdom to evaluate aerosol delivery by assessing lung distribution, pharmacokinetics and safety of inhaled treprostinil delivered by the AERx Essence system versus delivery with the Nebu-Tec OPTINEB*-ir nebulizer.
The latter device was used by Lung Rx, Inc. (Lung Rx), a wholly owned subsidiary of United Therapeutics Corporation, in the recently concluded TRIUMPH (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension) study of inhaled treprostinil in patients with Pulmonary Arterial Hypertension (PAH)... Aradigm's Press Release -